Stephanie A. Christenson, MD, MAS, summarizes core data presented at the 2024 American Thoracic Society (ATS) International Conference, including data on some promising biologics, like dupilumab and tezepelumab, which showed efficacy in patients with chronic obstructive pulmonary disease (COPD) and high eosinophils, offering hope for those prone to exacerbations. Ensifentrine, a PDE3/PDE4 inhibitor, also emerged as a potential treatment, diversifying therapeutic options beyond traditional inhalers. In addition, the variability in algorithmic classification of disease severity and lung function abnormalities raised important considerations, particularly regarding race-dependent classifications, which could significantly affect patients' lives and return-to-work decisions.
Overall, these findings suggest a changing landscape in COPD management, with potential new therapies on the horizon and a need for personalized approaches based on evolving research and diagnostic criteria.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: How Data From ATS 2024 Will Affect COPD Patient Care - Medscape - Jun 12, 2024.
Comments